StreetInsider.com News Articles

Form 144 Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 26 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26699688.html

Form 144 Tyra Biosciences, Inc. Filed by: NEXTECH VI ONCOLOGY SCSP

Fri, 26 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26699688.html

Jones Trading Starts Tyra Biosciences (TYRA) at Buy

Wed, 17 Jun 2026 07:08:21 -0400

Jones Trading analyst Matt Murray initiates coverage on Tyra Biosciences (NASDAQ: TYRA) with a Buy rating and a price target of $56.00.

For an analyst ratings summary and ratings history on Tyra Biosciences click here. For more ratings news on Tyra Biosciences click here.

Shares of Tyra Biosciences closed at $28.21 yesterday.

Oppenheimer Assumes Tyra Biosciences (TYRA) at Outperform

Wed, 17 Jun 2026 06:12:53 -0400

Oppenheimer analyst Mazahir Alimohamed assumes coverage on Tyra Biosciences (NASDAQ: TYRA) with a Outperform rating and a price target of $50.00.

For an analyst ratings summary and ratings history on Tyra Biosciences click here. For more ratings news on Tyra Biosciences click here.

Shares of Tyra Biosciences closed at $28.21 yesterday.

Tyra Biosciences (TYRA) PT Raised to $42 at BofA Securities

Wed, 10 Jun 2026 05:11:36 -0400

BofA Securities analyst Jason Zemansky raised the price target on Tyra Biosciences (NASDAQ: TYRA) to $42.00 (from $37.00) while maintaining a Buy rating.

The analyst comments "After a strong start to 2026, sentiment on Tyra has cooled despite seemingly little change to the story (since May: TYRA -25% vs. NBI flat). In our view, the weakness reflects a mix of macro pressures, profit-taking, and renewed concerns around SURF302—specifically whether dabogratinib (dabo) can deliver the requisite safety/ benefit profile required for early-stage NMIBC. Ahead of the Aug readout, we revisited the setup with our KOLs—including an investigator on J&J’s similar THOR-2 trial—and

Tyra Biosciences (TYRA) PT Raised to $42 at BofA Securities

Wed, 10 Jun 2026 05:11:36 -0400

BofA Securities analyst Jason Zemansky raised the price target on Tyra Biosciences (NASDAQ: TYRA) to $42.00 (from $37.00) while maintaining a Buy rating.

Raymond James Reiterates Strong Buy Rating on Tyra Biosciences (TYRA)

Thu, 04 Jun 2026 16:54:12 -0400

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $55.00 price target on Tyra Biosciences (NASDAQ: TYRA).

The analyst comments "Remain Strong Buy rated on TYRA shares and would recommend purchasing on current weakness after shares have retreated some 24% since 1Q26 earnings, primarily – we believe – on a number of misinterpretations and misattributions ahead of the all-important daborgratininb P2 SURF302 readout in IR NMIBC (expected in August). Specifically, on safety, we note that one transcript service misquoted CEO Todd Harris at a recent investor conference around expected grade 3 events. Second, on efficacy, closer scrutiny of JNJ’s

Form 8-K Tyra Biosciences, Inc. For: May 28

Tue, 02 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26591406.html

Form 8-K Tyra Biosciences, Inc. For: May 28

Tue, 02 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260602/26591406.html

Form 4 Tyra Biosciences, Inc. For: May 28 Filed by: Shah Rajeev M.

Mon, 01 Jun 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260601/26585309.html

Form 4 Tyra Biosciences, Inc. For: May 28 Filed by: Shah Rajeev M.

Mon, 01 Jun 2026 17:45:00 -0400

si-local-file:///var/storage/secattach/20260601/26585309.html

Form 4 Tyra Biosciences, Inc. For: May 28 Filed by: Gulfo Adele M.